Tonghua Dongbao Pharmaceutical Co Ltd600867
▼ NegativeCapitalrelevance
Termination of THDBH110 project and impairment of 16.8854 million yuan reduces first-half 2026 profit.

Tonghua Dongbao has decided to terminate the THDBH110 and THDBH110 capsule development project, and will fully record an asset impairment provision for the capitalized development costs of the project, totaling 16.8854 million yuan. The impairment will reduce the company's total profit for the first half of 2026 by 16.8854 million yuan.
Tonghua Dongbao Pharmaceutical Co LtdTermination of THDBH110 project and impairment of 16.8854 million yuan reduces first-half 2026 profit.